<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893074</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00026278</org_study_id>
    <secondary_id>R01DA025044</secondary_id>
    <nct_id>NCT00893074</nct_id>
  </id_info>
  <brief_title>The Effect of Prescription Medications in Marijuana Users</brief_title>
  <official_title>The Effect of Prescription Medications in Marijuana Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A subset of heavy marijuana users have trouble quitting marijuana use and the number of those
      seeking treatment for problems related to marijuana is increasing. The purpose of this
      research study is to investigate whether dronabinol can reduce withdrawal effects associated
      with stopping marijuana use, if dronabinol can reduce the rewarding effects of smoked
      marijuana, and whether there are any cognitive performance deficits associated with
      dronabinol doses that produce such effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Within-subjects cross-over evaluation of 0, 30, 60, and 120mg dronabinol per day on withdrawal, cognitive performance, and response to acute cannabis exposure</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Dronbinol doses were double blind and placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Effect of Marijuana Withdrawal</measure>
    <time_frame>Day 5 of the Dronabinol abstinence period</time_frame>
    <description>Total withdrawal based on a composite score of the Marijuana Withdrawal Checklist (range 0-32; higher scores indicate greater withdrawal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective &quot;Drug Effect&quot; After Smoked Marijuana</measure>
    <time_frame>Day 5 of the Dronabinol abstinence period</time_frame>
    <description>Subjective drug effects on a 100mm point Visual Analog Scale reported following acute cannabis dose administration during dronabinol maintenance, scale ranging 0-100, with 0 being no effect and 100 being maximum effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Assessed on Day 5 of dronabinol maintenance</time_frame>
    <description>Heart rate measured after acute cannabis exposure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>0, 30, 60, and 120mg dronabinol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol 30mg/day</intervention_name>
    <description>10mg dronabinol administered 3x/day for 5 days</description>
    <arm_group_label>0, 30, 60, and 120mg dronabinol</arm_group_label>
    <other_name>THC</other_name>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol 60mg/day</intervention_name>
    <description>20mg dronabinol administered 3x/day for 5 days</description>
    <arm_group_label>0, 30, 60, and 120mg dronabinol</arm_group_label>
    <other_name>THC</other_name>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol 120mg/day</intervention_name>
    <description>40mg dronabinol administered 3x/day for 5 days</description>
    <arm_group_label>0, 30, 60, and 120mg dronabinol</arm_group_label>
    <other_name>THC</other_name>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo dronabinol administered 3x/day for 5 days</description>
    <arm_group_label>0, 30, 60, and 120mg dronabinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current use of marijuana

          -  able to give informed consent

        Exclusion Criteria:

          -  dependence on drug other than marijuana

          -  pregnant, breast feeding, or planning to become pregnant within the next 3 months

          -  currently seeking treatment for cannabis-related problems or otherwise trying to
             reduce use

          -  use of cannabis under the guidance of a physician for a medical disorder

          -  unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)

          -  allergy to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2013 Feb 1;128(1-2):64-70. doi: 10.1016/j.drugalcdep.2012.08.001. Epub 2012 Aug 22.</citation>
    <PMID>22921474</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>withdrawal</keyword>
  <keyword>acute effects</keyword>
  <keyword>cognitive performance</keyword>
  <keyword>Marijuana Use</keyword>
  <keyword>Marijuana Abstinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0, 30, 60, and 120mg Dronabinol</title>
          <description>0, 30, 60, and 120mg Dronabinol administered for 5 consecutive days in a double blind, placebo controlled study, with dose administered in a random order to the same study participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Participant</title>
          <description>Participants who received active drug as part of the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Effect of Marijuana Withdrawal</title>
        <description>Total withdrawal based on a composite score of the Marijuana Withdrawal Checklist (range 0-32; higher scores indicate greater withdrawal).</description>
        <time_frame>Day 5 of the Dronabinol abstinence period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0mg daily dronabinol administered for 5 days</description>
          </group>
          <group group_id="O2">
            <title>30mg Dronabinol</title>
            <description>30mg daily dronabinol (10mg tid) administered for 5 days</description>
          </group>
          <group group_id="O3">
            <title>60mg Dronabinol</title>
            <description>60mg daily dronabinol (20mg tid) administered for 5 days</description>
          </group>
          <group group_id="O4">
            <title>120mg Dronabinol</title>
            <description>120mg daily dronabinol (40mg tid) administered for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Effect of Marijuana Withdrawal</title>
          <description>Total withdrawal based on a composite score of the Marijuana Withdrawal Checklist (range 0-32; higher scores indicate greater withdrawal).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.9"/>
                    <measurement group_id="O2" value="4.1" spread="0.9"/>
                    <measurement group_id="O3" value="2.9" spread="0.7"/>
                    <measurement group_id="O4" value="1.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective &quot;Drug Effect&quot; After Smoked Marijuana</title>
        <description>Subjective drug effects on a 100mm point Visual Analog Scale reported following acute cannabis dose administration during dronabinol maintenance, scale ranging 0-100, with 0 being no effect and 100 being maximum effect</description>
        <time_frame>Day 5 of the Dronabinol abstinence period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo dronabinol maintenance</description>
          </group>
          <group group_id="O2">
            <title>30mg Dronabinol</title>
            <description>30mg (10mg tid) dronabinol maintenance</description>
          </group>
          <group group_id="O3">
            <title>60mg Dronabinol</title>
            <description>60mg (20mg tid) dronabinol maintenance</description>
          </group>
          <group group_id="O4">
            <title>120mg Dronabinol</title>
            <description>120mg (40mg tid) dronabinol maintenance</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective &quot;Drug Effect&quot; After Smoked Marijuana</title>
          <description>Subjective drug effects on a 100mm point Visual Analog Scale reported following acute cannabis dose administration during dronabinol maintenance, scale ranging 0-100, with 0 being no effect and 100 being maximum effect</description>
          <units>mm of subjective drug effect</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="3"/>
                    <measurement group_id="O2" value="28" spread="3"/>
                    <measurement group_id="O3" value="24" spread="3"/>
                    <measurement group_id="O4" value="29" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Heart rate measured after acute cannabis exposure</description>
        <time_frame>Assessed on Day 5 of dronabinol maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo dronabinol maintenance</description>
          </group>
          <group group_id="O2">
            <title>30mg Dronabinol</title>
            <description>30mg (10mg tid) dronabinol maintenance</description>
          </group>
          <group group_id="O3">
            <title>60mg Dronabinol</title>
            <description>60mg (20mg tid) dronabinol maintenance</description>
          </group>
          <group group_id="O4">
            <title>120mg Dronabinol</title>
            <description>120mg (40mg tid) dronabinol maintenance</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart rate measured after acute cannabis exposure</description>
          <units>beats per minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="2"/>
                    <measurement group_id="O2" value="85" spread="2"/>
                    <measurement group_id="O3" value="80" spread="1"/>
                    <measurement group_id="O4" value="76" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>51 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo maintenance</description>
        </group>
        <group group_id="E2">
          <title>30mg</title>
          <description>30mg dronabinol maintenance</description>
        </group>
        <group group_id="E3">
          <title>60mg</title>
          <description>60mg dronabinol maintenance</description>
        </group>
        <group group_id="E4">
          <title>120mg</title>
          <description>120mg dronabinol maintenance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="10" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Vandrey, PhD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-4036</phone>
      <email>rvandrey@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

